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ORIGINAL ARTICLEProspective study of pathogens in asymptomatic travellers and those with
diarrhoea: aetiological agents revisitedT. Lääveri1,2, J. Antikainen3, S. H. Pakkanen4, J. Kirveskari3 and A. Kantele1,2,5,6
1) Department of Medicine, University of Helsinki, Helsinki, 2) Inﬂammation Centre, Clinic of Infectious Diseases, University of Helsinki and Helsinki University
Hospital, 3) Department of Clinical Microbiology, Helsinki University Hospital, HUSLAB, 4) Department of Bacteriology and Immunology, University of
Helsinki, 5) Aava Travel Clinic, Medical Centre Aava, Helsinki, Finland and 6) Unit of Infectious Diseases, Department of Medicine/Solna, Karolinska Institutet,
Stockholm, SwedenAbstractTravellers’ diarrhoea (TD) remains the most frequent health problem encountered by visitors to the (sub)tropics. Traditional stool culture
identiﬁes the pathogen in only 15% of cases. Exploiting PCR-based methods, we investigated TD pathogens with a focus on asymptomatic
travellers and severity of symptoms. Pre- and post-travel stools of 382 travellers with no history of antibiotic use during travel were
analysed with a multiplex quantitative PCR for Salmonella, Yersinia, Campylobacter, Shigella, Vibrio cholerae and ﬁve diarrhoeagenic
Escherichia coli: enteroaggregative (EAEC), enteropathogenic (EPEC), enterotoxigenic (ETEC), enterohaemorrhagic (EHEC) and
enteroinvasive (EIEC). The participants were categorized by presence/absence of TD during travel and on return, and by severity of
symptoms. A pathogen was indentiﬁed in 61% of the asymptomatic travellers, 83% of those with resolved TD, and 83% of those with
ongoing TD; 25%, 43% and 53% had multiple pathogens, respectively. EPEC, EAEC, ETEC and Campylobacter associated especially with
ongoing TD symptoms. EAEC and EPEC proved more common than ETEC. To conclude, modern methodology challenges our
perception of stool pathogens: all pathogens were common both in asymptomatic and symptomatic travellers. TD has a multibacterial
nature, but diarrhoeal symptoms mostly associate with EAEC, EPEC, ETEC and Campylobacter.
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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E-mail: anu.kantele@hus.ﬁIntroductionEncountered by 10%–40% [1] of travellers visiting emerging
economies, travellers’ diarrhoea (TD) is the most common
travel-associated health problem. Although approximately 80%
of the cases with conﬁrmed microbiological aetiology are© 2016 The Authors. Published by El
This is an open access artiascribed to bacterial pathogens [1,2], numerous studies have, in
lack of proper methodology, failed to recognize the responsible
microorganism in up to half of the cases even when including
viral and parasitic pathogens [1–4].
Traditionally, enterotoxigenic Escherichia coli (ETEC) has
been considered the major causative pathogen for TD [1,2], but
in recent research, enteroaggregative E. coli (EAEC) [5–8] and
enteropathogenic E. coli (EPEC) [5,6,8,9] have been reported
even more frequently. Campylobacter has been a common
ﬁnding in travellers to South East Asia [1,2]. Viral pathogens,
enterohaemorrhagic E. coli (EHEC) and enteroinvasive E. coli
(EIEC), Shigella spp., Salmonella spp., and parasites have been
detected less frequently [1,2]. The role of other pathogens suchClin Microbiol Infect 2016; 22: 535–541
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Bacteroides fragilis [11] remains to be established.
The new methods provide far better coverage of the variety
of aetiological agents than older approaches [5,7,12,13] and
decrease the rate of unexplained TD cases to 5%–24% [6–8].
Furthermore, results obtained either by PCR [7–9,14] or
culture-based methods [3,4,15] suggest that diarrhoeal patho-
gens are found even in asymptomatic travellers or travellers
whose symptoms have already resolved [15]. However, in many
studies the ‘No TD’ control group may have comprised, besides
asymptomatic cases, also those with mild TD or participants
whose TD symptoms had resolved before the time of sampling
[3,4,7,9,14]. Even non-travellers have been used as controls
[9,16]. Just a handful of investigations have applied strict criteria
to the No TD control group [8,17,18].
To revisit the role of various TD pathogens, we explored
separately travellers with ongoing disease, resolved disease and
without any diarrhoeal symptoms during their entire journeys.
The strict categorization is expected to provide accurate data
on the frequency of symptomless carriage and so the actual
signiﬁcance of the various TD pathogens.Material and methodsStudy population
Participants were recruited prospectively at the Travel Clinic at
AavaMedicalCentre,Helsinki, Finland, between1March 2009 and
28 February 2010, among clients planning a journey outside the
Nordic countries for a minimum of four nights. Of the initial 526
volunteers, 459 met the inclusion criteria, i.e. delivered (a) a pre-
travel stool sample; (b) a completed pre-travel questionnaire; (c)
a post-travel sample from the ﬁrst (or second) stool after arrival;
and (d) a completed post-travel questionnaire. Data on antimi-
crobial medicationwas available for 456/459 participants, 74 (16%)
of whom reported having taken antibiotics during travel; the 382
with no antibiotic use (doxycycline as malaria prophylaxis not
included) were included in the ﬁnal analyses (Fig. 1).
The study protocol was approved by the Ethics Committee
of the Department of Medicine, Helsinki University Hospital.
Written informed consent was obtained from all participants.
We have earlier reported ﬁndings of resistant intestinal mi-
crobes in the same population [19], and included in our
methodological study pilot data on diarrhoeal pathogens of 96
participants with TD [5].
Deﬁnition of travellers’ diarrhoea and its severity
Travellers’ diarrhoea was deﬁned according to theWHO criteria
[20] as the passage of three or more loose or liquid stools per day
or, alternatively, more frequently than is normal for the individual.© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceEach traveller was classiﬁed in one of three categories:
Asymptomatic (those having stayed free of any diarrhoeal symp-
toms during the entire journey), Resolved TD, and Ongoing TD.
Ongoing symptoms were characterized according to degree
of severity: severe TD was deﬁned as six or more diarrhoeal
stools per day, TD accompanied by fever or haemorrhagic
stools, or TD requiring hospitalization; mild TD involved one or
two diarrhoeal stools per day; moderate TD comprised those
with TD not fulﬁlling the criteria of severe or mild TD.
Stool collection
The stool samples were collected as swabs in Copan M40
Transystem tubes (CopanDiagnostics, Brescia, Italy) andmailed in
special boxes, reaching the laboratory in 1–3 days. Once arrived,
total nucleic acids were puriﬁed directly from stool swabs as
described previously [5].
Identiﬁcation of the stool pathogens
The analyses were carried out with a validated multiplex
quantitative PCR method that was recently described [5] and
thereafter applied to a group of 45 travellers visiting Benin
together [8]. It covers the following pathogens: diarrhoeagenic
E. coli including EPEC, ETEC, EAEC, EHEC and EIEC and
Shigella as well as Salmonella spp., pathogenic Yersinia enter-
ocolitica, Yersinia pseudotuberculosis and Yersinia pestis, Vibrio
cholerae and Campylobacter jejuni/coli. The assay allows rapid and
simultaneous examination of all these pathogens, providing
results in just 4 h.
The questionnaires
The pre-travel questionnaire gathered information about the
demographics and possible diarrhoeal symptoms at the time of
ﬁrst faecal sample. The post-travel questionnaire assessed
diarrhoeal and other symptoms while abroad and immediately
after returning home, in addition to which it covered countries
visited and medication taken over the journey.
Statistical analysis
For categorical variables the statistical analyses were carried
out with chi-squared tests, Fisher’s exact test or binary logistic
regression analysis when applicable. Statistical signiﬁcance was
deﬁned as p < 0.05.The statistical analysis was conducted using
SPSS 22 software (IBM Corp, Armonk, NY, USA).ResultsDemographics, travel itinerary and TD symptoms
Demographic and travel data are shown in Table 1 and details
of TD symptoms are shown in Tables 2 and 3. In all, 65% of theiology and Infectious Diseases, CMI, 22, 535–541
nses/by-nc-nd/4.0/).
FIG. 1. Study protocol for investigating aetiology of travellers’ diarrhoea with respect to occurrence and severity among Finnish travellers.
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erate in 34% and mild in 43%. At the time of post-travel stool
sampling, 30% of the participants reported having ongoing
diarrhoea, whereas the symptoms of 35% had already resolved.
Bacterial pathogens in stool samples
Findings in pre-travel stool samples. Of the pre-travel samples, 4%
(14/382) were positive: 2% had EPEC, 1% had EAEC, 0.5% had
ETEC and 0.3% had Campylobacter. One of these participants
had mild diarrhoea at the time of sampling.
Findings in post-travel stool samples. The post-travel stool
ﬁndings related to TD are presented in Table 2. A bacterial
pathogen was detected in 75% of the samples. EPEC (46%) and
EAEC (45%) proved the most common ﬁndings, followed by
ETEC (20%), EHEC (9%), Campylobacter (7%), Salmonella (2%)
and Shigella/EIEC (1%). Multiple pathogens were found in 40%
of the post-travel samples.
Comparison of pathogen ﬁndings between the three categories:
asymptomatic, resolved TD and ongoing TD. EPEC and ETEC
proved more frequent among travellers with ongoing TD (55%
and 37%, respectively; Table 2) than those with resolved disease
(41% and 17%) and the asymptomatic group (45% and 9%).
EAEC and Campylobacter, by contrast, were equally common
among those with ongoing TD (51% and 8%) and resolved TD
(57% and 12%), but less frequent in the asymptomatic group
(28% and 1%). Multiple pathogens were detected in 25% of the
samples of the asymptomatic participants, 43% in the group
with resolved TD and 53% in the ongoing TD.© 2016 The Authors. Published by Elsevier Ltd on behalf
This is an open access articFindings in participants with mild TD proved similar to those
of participants with moderate or severe ongoing disease
(Table 3).
Discussion
Diarrhoea is the most common reason for returning travellers
to contact healthcare [21,22]. Whereas the traditional labora-
tory diagnostics available in most clinical settings only cover a
small number of diarrhoeal pathogens, the fast and accurate
modern molecular methods, which allow diagnosis within hours
instead of days, extend the coverage to the most common
pathogens, i.e. diarrhoeagenic E. coli [5,12,13]. Our primary
ﬁnding was that travellers carry various TD pathogens much
more commonly than is generally believed: pathogens were
detected in the stools of participants with resolved symptoms
and even those remaining asymptomatic. Multiple pathogens
proved common not only among participants with ongoing
symptoms, but also the asymptomatic.
Findings in the asymptomatic group
One of our most impressive ﬁndings was that bacterial patho-
gens were detected in more than half (61%) of asymptomatic
travellers, and multiple pathogens were found in almost half of
these (42%). As this group only included those without any
diarrhoeal symptoms during travel, the pathogens detected
were not remains of bacteria having previously caused TD. A
high proportion of pathogens has also been reported for
asymptomatic travellers in a few earlier studies [3,7–9,14].of European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 535–541
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).










Total 382 135 (35) 132 (35) 115 (30)
Sex
Male 149 (39) 54 (40) 53 (37) 42 (40)
Female 233 (61) 81 (60) 79 (63) 73 (60)
Age (years)
Age (mean) 40
(SD 17; range 0–77)
43
(SD 19; range 1–77)
36
(SD 17; range 0–76)
40
(SD 15; range 1–72)
Age group (years)
0–17 31 (8) 16 (52) 11 (35) 4 (13)
18–30 105 (27) 18 (17) 45 (43) 42 (40)
31–50 130 (34) 45 (35) 46 (35) 39 (30)
51–64 83 (22) 38 (46) 20 (24) 25 (30)
over 65 33 (9) 18 (55) 10 (30) 5 (15)
Destination1
South Asia 52 (14) 12 (23) 19 (36) 21 (40)
South East Asia 91 (24) 23 (25) 48 (53) 20 (22)
East Asia 5 (1) 3 (60) 0 (0) 2 (40)
Sub-Saharan Africa 171 (45) 61 (36) 53 (31) 57 (33)
North Africa and Middle East 11 (3) 7 (64) 1 (9) 3 (27)
Latin America 36 (9) 16 (44) 11 (31) 9 (25)
Europe, North America and Australia 16 (4) 13 (81) 0 (0) 3 (19)
Duration of travel in days, mean
(information missing 5)
21 (median 16, SD 17
range 5–146)
16 (median 15, SD 10
range 5–81)
29 (median 19, SD 24
range 5–146)
18 (median 15, SD 10,
range 5–60)
7 days or less 11 (3) 8 (6) 1 (1) 2 (2)
8–14 days 111 (29) 52 (39) 18 (14) 41 (37)
15–30 days 196 (52) 64 (47) 74 (57) 58 (52)
31 days or more 59 (16) 11 (8) 37 (29) 11 (10)
Chronic underlying illness2 78 (20) 40 (30) 22 (17) 16 (14)
The data are given separately for those with no TD during journey, those with resolved, and those with ongoing TD.
1Travel destinations were grouped into regions as described earlier [22].
2Asthma, cardiovascular disease, diabetes, coeliac disease, inﬂammatory bowel disease, epilepsy, rheumatic disease, malignancy during the past 10 years.
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EAEC and EPEC were the two most common pathogens among
the asymptomatic travellers, whereas, contrary to ﬁndings
elsewhere [3,7], Campylobacter and ETEC proved rare. This
may have resulted from our rigorous inclusion criteria for the
group, whereas other studies may have included travellers with
resolved or mild symptoms. All these data emphasize the
importance of having an asymptomatic control group consisting
of travellers with no symptoms during their journeys, when
assessing the clinical signiﬁcance of the various stool pathogens.
Findings in TD groups
The pathogen ﬁndings for travellers with TD differed signiﬁ-
cantly from those for the asymptomatic, whereas there was no
difference among those with ongoing TD, i.e. between partici-
pants with mild, moderate or severe diarrhoea. In TD, EAEC
and EPEC proved more prevalent than ETEC, which has
traditionally been considered the central TD pathogen [1,2]. In
recent research [6–8], EAEC and EPEC have been detected
more frequently than ETEC, probably because of deploying
advanced methods that afford better coverage of the pathogens.
We found an association between diarrhoeal symptoms and
EPEC, EAEC, ETEC and Campylobacter. A comparison between
participants with ongoing symptoms and those with resolved
TD suggests that ETEC and EPEC disappear from the stools© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceafter resolution of symptoms, whereas EAEC and Campylo-
bacter persist for longer.
We found EAEC more frequently in the stools of travellers
with ongoing or resolved symptoms than the asymptomatic
group, conﬁrming earlier reports of EAEC’s role as a TD
pathogen [7,23,24]. However, as EAEC is common also among
the asymptomatic, its signiﬁcance in individual cases should be
viewed with caution.
This is one of the ﬁrst studies enabling comparison between
EPEC ﬁndings in post-travel stools of symptomatic and
asymptomatic travellers. Until now, despite being recognized as
a major pathogen in childhood diarrhoea in developing coun-
tries [25], EPEC’s role in TD has been disputable: its frequency
has been similar among those with and without TD [3,8,14,17],
travel histories of controls have not been provided [16], not all
have been travellers [9], or a control group has been lacking
altogether [6]. We detected EPEC more frequently in ongoing
TD than among asymptomatic participants or those with
symptoms resolved, which suggests a role for this pathogen in
adult TD. Indeed, these results and lack of earlier data on EPEC
[1,2] point to a need for more research into its role in TD.
Inmany earlier TD studies [2], multiple pathogen ﬁndings have
been rare. In our data, half (53%) of those with ongoing TD
symptoms and every fourth (25%) asymptomatic traveller had
two or more pathogens. This accords with a few other recentiology and Infectious Diseases, CMI, 22, 535–541
nses/by-nc-nd/4.0/).




No TD at time of
sampling Univariate statistics









n (%) n (%) n (%) n (%) OR (95% CI) p OR (95% CI) p OR (95% CI) p
Total: 382 115 (30) 135 (35) 132 (35)
Any bacterial pathogen 287 (75) 96 (83) 82 (61) 109 (83) 3.3 (1.8–6.0) <0.001 0.9 (0.5–1.8) 0.851 3.1 (1.7–5.4) <0.001
Two or more pathogens 152 (40) 61 (53) 34 (25) 57 (43) 2.5 (1.3–4.5)* 0.004 1.6 (0.9–2.8)* 0.105 1.5 (0.9–2.6)* 0.139
Diarrhoeagenic
E. coli (DEC)
277 (73) 95 (83) 81 (60) 101 (77) 2.2 (1.3–3.7) 0.004 1.5 (0.8–2.7) 0.239 3.2 (1.8–5.7) <0.001
EPEC 174 (46) 63 (55) 57 (42) 54 (41) 1.7 (1.0–2.7) 0.048 1.6 (1.1–2.9) 0.030 0.9 (0.6–1.5) 0.828
EAEC 171 (45) 58 (50) 38 (28) 75 (57) 2.6 (1.5–4.4) <0.001 0.7 (0.5–1.3) 0.316 3.4 (2.0–5.6) <0.001
ETEC 76 (20) 42 (37) 12 (9) 22 (17) 5.9 (2.9–11.9) <0.001 2.9 (1.6–5.2) <0.001 2.1 (1.0–4.3) 0.060
EHEC 34 (9) 7 (6) 10 (7) 17 (13) 0.8 (0.3–2.2) 0.680 0.4 (0.2–1.1) 0.079 1.8 (0.8–4.2) 0.143
Non-DEC 36 (9) 12 (10) 4 (3) 20 (15) 3.8 (1.2–12.2) 0.024 0.7 (0.3–1.4) 0.273 5.8 (1.9–17.6) 0.002
Campylobacter 26 (7) 9 (8) 1 (1) 16 (12) 11.4 (1.4–91.2) 0.022 0.6 (0.3–1.5) 0.268 18.5 (2.4–141.5) 0.005
Salmonella 29 (2) 3 (3) 3 (2) 3 (2) 1.2 (0.2–6.0) 0.842 1.1 (0.2–5.8) 0.864 1.0 (0.2–5.2) 0.978
EIEC/Shigella 3 (1) 1 (1) 0 (0) 2 (2) N/A 0.996 0.6 (0.1–6.4) 0.648 N/A 0.996
Vibrio cholerae 0 (0) 0 (0) 0 (0) 0 (0) N/A N/A N/A N/A N/A N/A
Yersinia spp. 0 (0) 0 (0) 0 (0) 0 (0) N/A N/A N/A N/A N/A N/A
Results are presented in relation to symptoms during travel and at the time of post-travel stool sampling. The following bacterial pathogens were explored: enteropathogenic (EPEC),
enteroaggregative (EAEC), enterotoxigenic (ETEC), enterohaemorrhagic (EHEC) and enterionvasive (EIEC) Escherichia coli or Shigella, as well as Salmonella spp., Yersinia spp., Vibrio
cholerae and Campylobacter coli/jejuni. Pathogens were found in all groups: Ongoing TD, Resolved TD and Asymptomatic, frequency decreasing respectively.
*Compared with one pathogen.
1WHO deﬁnition: passage of three or more loose or liquid stools per day or, alternatively, more frequently than is normal for the individual [20].
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[3,7–9,11,14]. Importantly, in many earlier studies [2] diar-
rhoeagenic E. coli have not been comprehensively explored.
Prospective research using modern molecular methods is
needed to pinpoint the actual involvement of each pathogen.
Considerations of the PCR method
While up to 50% of cases have remained unexplained in
aetiological investigations of TD [1–4], the PCR-based
method used herein revealed a pathogen in 83%, concurring
with recent studies employing these techniques [6–8]. In
addition to providing a broader coverage of stool pathogens,
PCR methods are more sensitive than stool cultures. The
present method has been validated with culture conﬁrmation
as described earlier [5].
Our ﬁnding of multiple pathogens in 40% of all TD stools
attests to the signiﬁcance of the methodology used: the role ofTABLE 3. Relation between ﬁndings of EPEC, EAEC, ETEC, Campyl
Total
No TD Ongoing TD sympto
Asymptomatic Mild TD Mode
n (%) n (%) n (%) n (%)
Total 250 135 (50) 42 (17) 43 (17
Any bacterial pathogen 96 (71) 82 (61) 35 (83) 37 (86
EPEC 120 (48) 57 (42) 22 (52) 28 (65
EAEC 96 (38) 38 (28) 19 (45) 26 (60
ETEC 54 (22) 12 (9) 11 (26) 19 (44
Campylobacter 10 (4) 1 (1) 3 (7) 3 (7)
Data given on those remaining asymptomatic during travel and those with ongoing TD symp
EPEC, enteropathogenic Escherichia coli; EAEC, enteroaggregative E. coli; ETEC, enterotoxige
© 2016 The Authors. Published by Elsevier Ltd on behalf
This is an open access articeach pathogen can only be evaluated if data on potential other
diarrhoeal microbes are available. Although a broader coverage
of the range of pathogens will certainly enhance the accuracy of
future studies, it will also entail new challenges to interpreting
results, for example in cases with multiple pathogens.
Limitations
Three limitations deserve to be discussed. First, the participants
provided the second stool sample only after travel and, therefore,
the symptoms may already have resolved and some pathogens
disappeared, whereas others not initially causing the symptoms
may still be present. To tackle this problem, we made separate
comparisons between the groups with ongoing and resolved
symptoms (results discussed above). Our results may nonetheless
underestimate the proportion of certain pathogens, especially
ETEC, which has been suggested to disappear rapidly from the
stools [15,26]. The second limitation, the inablility of quantitativeobacter and severity of ongoing TD symptoms at sampling time
ms Univariate statistics
rate TD Severe TD
Severity of ongoing TD symptoms, p-valuen (%)
) 30 (12)
) 24 (80) 0.791
) 13 (43) 0.170
) 13 (43) 0.248
) 12 (40) 0.204
3 (10) 0.875
toms at time of sampling (n = 250).
nic E. coli; TD, tavellers’ diarrhoea.
of European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 535–541
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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actually constitutes a shortcoming in all studies employing such
assays. On the other hand, free DNA is unlikely to resist active
DNAases during its entire passage through the gastrointestinal
tract [27,28]. Third, we did not cover parasitic, viral and some
other potential bacterial pathogens. Analysing themmight further
diminish the proportion of unexplained TD cases.
Clinical considerations
Adopting the novel advanced methodology into routine use,
clinicians have new challenges to meet: when to take the test
and how to interpret the results. We instruct our healthcare
professionals that tests are warranted only in instances where
microbiological diagnostics would earlier have been used.
Evaluating the signiﬁcance of the various pathogens detected is
complicated by the great proportion of multiple bacterial
ﬁndings (53% of cases with ongoing symptoms). The most
common pathogens, diarrhoeagenic E. coli, usually do not
require antibiotic treatment. The same applies to most TD
cases: the great majority (up to 78%) remain mild or moderate
and resolve spontaneously [8,29,30]. Indeed, caution with an-
tibiotics is also highlighted in our recent study showing that
antibiotics taken against TD predispose travellers to coloniza-
tion with multiresistant intestinal bacteria [22].ConclusionPCR-based methodology changes our perception of stool
pathogens, because all pathogens are seen in travellers,
asymptomatic and symptomatic alike, both showing high rates
of detection. In light of our analysis, it appears vital that future
studies include an asymptomatic control group. Our results
support the current view that TD only rarely requires antibiotic
treatment. The data discourage prescribing antimicrobials
merely on the basis of microbiological ﬁndings, for some of the
pathogens detected may not have caused any symptoms. TD
has a multibacterial nature, yet diarrhoeal symptoms are mostly
associated with EAEC, EPEC, ETEC and Campylobacter.Transparency declarationAll authors declare no conﬂicts of interest.Authors’ contributionsStudy concept and design— JA, JK, AK; drafting of manu-
script—TL, AK; statistical analysis—TL. All authors© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licecontributed to acquisition of data analysis and interpretation
of results and they all gave ﬁnal approval of the version
published.AcknowledgementsThis work was supported by the Finnish Governmental Subsidy
for Health Science Research (grant numbers: TYH2012141,
TYH 2013218 and TYH 2014216), the SSAC Foundation (grant
number SLS-504141) and the Paulo Foundation. We express
our gratitude to the late Dr Jukka Riutta for recruiting the
patients. We also thank the nurses at the Travel Clinic of Aava
Medical Centre for help in recruiting the volunteers, the
personnel of Helsinki University Hospital Laboratory for pro-
cessing the stool specimens, and Jukka Ollgren for expert
advice in statistical analyses.References[1] Steffen R, Hill DR, DuPont HL. Traveler’s diarrhea: a clinical review.
JAMA 2015;313:71–80.
[2] Shah N, DuPont HL, Ramsey DJ. Global etiology of travelers’ diarrhea:
systematic review from 1973 to the present. Am J Trop Med Hyg
2009;80:609–14.
[3] Pandey P, Bodhidatta L, Lewis M, Murphy H, Shlim DR, Cave W, et al.
Travelers’ diarrhea in Nepal: an update on the pathogens and antibiotic
resistance. J Travel Med 2011;18:102–8.
[4] Riddle MS, Rockabrand DM, Schlett C, Monteville MR, Frenck RW,
Romine M, et al. A prospective study of acute diarrhea in a cohort of
United States military personnel on deployment to the Multinational
Force and Observers, Sinai, Egypt. Am J Trop Med Hyg 2011;84:59–64.
[5] Antikainen J, Kantele A, Pakkanen SH, Lääveri T, Riutta J, Vaara M, et al.
A quantitative polymerase chain reaction assay for rapid detection of 9
pathogens directly from stools of travelers with diarrhea. Clin Gas-
troenterol Hepatol 2013;11:1300–7.
[6] Paredes-Paredes M, Okhuysen PC, Flores J, Mohamed JA, Padda RS,
Gonzalez-Estrada A, et al. Seasonality of diarrheagenic Escherichia coli
pathotypes in the US students acquiring diarrhea in Mexico. J Travel
Med 2011;18:121–5.
[7] Paschke C, Apelt N, Fleischmann E, Perona P, Walentiny C, Loscher T,
et al. Controlled study on enteropathogens in travellers returning from
the tropics with and without diarrhoea. Clin Microbiol Infect 2011;17:
1194–200.
[8] Lääveri T, Pakkanen SH, Antikainen J, Riutta J, Mero S, Kirveskari J,
et al. High number of diarrhoeal co-infections in travellers to Benin,
West Africa. BMC Infect Dis 2014;14:81.
[9] Bruijnesteijn van Coppenraet LE, Dullaert-de Boer M, Ruijs GJ, van der
Reijden WA, van der Zanden AG, Weel JF, et al. Case-control com-
parison of bacterial and protozoan microorganisms associated with
gastroenteritis: application of molecular detection. Clin Microbiol
Infect 2015;21:592.e9–592.e19.
[10] Chongsuvivatwong V, Chariyalertsak S, McNeil E, Aiyarak S,
Hutamai S, Dupont HL, et al. Epidemiology of travelers’ diarrhea in
Thailand. J Travel Med 2009 May– Jun;16(3):179–85.
[11] Jiang ZD, Dupont HL, Brown EL, Nandy RK, Ramamurthy T, Sinha A,
et al. Microbial etiology of travelers’ diarrhea in Mexico, Guatemala,iology and Infectious Diseases, CMI, 22, 535–541
nses/by-nc-nd/4.0/).
CMI Lääveri et al. Pathogens in asymptomatic travellers and those with diarrhoea 541and India: importance of enterotoxigenic Bacteroides fragilis and
Arcobacter species. J Clin Microbiol 2010 Apr;48(4):1417–9.
[12] Youmans BP, Ajami NJ, Jiang ZD, Petrosino JF, DuPont HL,
Highlander SK. Development and accuracy of quantitative real-time
polymerase chain reaction assays for detection and quantiﬁcation of
enterotoxigenic Escherichia coli (ETEC) heat labile and heat stable toxin
genes in travelers’ diarrhea samples. Am J Trop Med Hyg 2014;90:
124–32.
[13] Liu J, Kabir F, Manneh J, Lertsethtakarn P, Begum S, Gratz J, et al.
Development and assessment of molecular diagnostic tests for 15
enteropathogens causing childhood diarrhoea: a multicentre study.
Lancet Infect Dis 2014;14:716–24.
[14] Keskimäki M, Mattila L, Peltola H, Siitonen A. Prevalence of diar-
rheagenic Escherichia coli in Finns with or without diarrhea during a
round-the-world trip. J Clin Microbiol 2000;38:4425–9.
[15] Adachi JA, Ericsson CD, Jiang ZD, DuPont MW, Pallegar SR,
DuPont HL. Natural history of enteroaggregative and enterotoxigenic
Escherichia coli infection among US travelers to Guadalajara, Mexico.
J Infect Dis 2002;185:1681–3.
[16] Keskimäki M, Eklund M, Pesonen H, Heiskanen T, Siitonen A, Study
Group. EPEC, EAEC and STEC in stool specimens: prevalence and
molecular epidemiology of isolates. Diagn Microbiol Infect Dis
2001;40:151–6.
[17] Schultsz C, van den Ende J, Cobelens F, Vervoort T, van Gompel A,
Wetsteyn JC, et al. Diarrheagenic Escherichia coli and acute and
persistent diarrhea in returned travelers. J Clin Microbiol 2000;38:
3550–4.
[18] Cohen MB, Hawkins JA, Weckbach LS, Staneck JL, Levine MM,
Heck JE. Colonization by enteroaggregative Escherichia coli in travelers
with and without diarrhea. J Clin Microbiol 1993;31:351–3.
[19] Kantele A, Lääveri T, Mero S, Vilkman K, Pakkanen SH, Ollgren J, et al.
Antimicrobials increase travelers’ risk of colonization by extended-
spectrum betalactamase-producing Enterobacteriaceae. Clin Infect Dis
2015;60:837–46.
[20] World Health Organization (WHO) Health topics: Diarrhea. Available
at: http://www.who.int/topics/diarrhoea/en/. Accessed 17.01.16.© 2016 The Authors. Published by Elsevier Ltd on behalf
This is an open access artic[21] Harvey K, Esposito DH, Han P, Kozarsky P, Freedman DO, Plier DA,
et al. Surveillance for travel-related disease—GeoSentinel surveillance
system, United States, 1997–2011. MMWR Surveill Summ 2013;62:
1–23.
[22] Hill DR. Health problems in a large cohort of Americans traveling to
developing countries. J Travel Med 2000;7:259–66.
[23] Adachi JA, Jiang ZD, Mathewson JJ, Verenkar MP, Thompson S, Mar-
tinez-Sandoval F, et al. Enteroaggregative Escherichia coli as a major
etiologic agent in traveler’s diarrhea in 3 regions of the world. Clin
Infect Dis 2001;32:1706–9.
[24] Jiang ZD, Greenberg D, Nataro JP, Steffen R, DuPont HL. Rate of
occurrence and pathogenic effect of enteroaggregative Escherichia coli
virulence factors in international travelers. J Clin Microbiol 2002;40:
4185–90.
[25] Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH,
Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in
infants and young children in developing countries (the Global Enteric
Multicenter Study, GEMS): a prospective, case–control study. Lancet
2013;382(9888):209–22.
[26] Lindsay BR, Chakraborty S, Harro C, Li S, Nataro JP, Sommerfelt H,
et al. Quantitative PCR and culture evaluation for enterotoxigenic
Escherichia coli (ETEC) associated diarrhea in volunteers. FEMS
Microbiol Lett 2014;352:25–31.
[27] Netherwood T, Martin-Orue SM, O’Donnell AG, Gockling S,
Graham J, Mathers JC, et al. Assessing the survival of transgenic plant
DNA in the human gastrointestinal tract. Nat Biotechnol 2004;22:
204–9.
[28] Weerkamp AH, de Vos WM. Genetic marking of Lactococcus lactis
shows its survival in the human gastrointestinal tract. Appl Environ
Microbiol 1995;61:2771–4.
[29] Soonawala D, Vlot JA, Visser LG. Inconvenience due to travelers’
diarrhea: a prospective follow-up study. BMC Infect Dis 2011;11:322.
[30] Belderok SM, van den Hoek A, Kint JA, Schim van der Loeff MF,
Sonder GJ. Incidence, risk factors and treatment of diarrhoea among
Dutch travellers: reasons not to routinely prescribe antibiotics. BMC
Infect Dis 2011;11:295.of European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 535–541
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
